COMPANY PROFILE / #952
Inocras
San Diego, CAVenture Capital-Backed
OVERVIEW
Developer of a genome-based big data platform designed to pave the way for a new era of personalized precision medicine. The company's platform offers insights through the precise interpretation of full-length genome big data, enabling clients to employ the information effectively in their operations.
已融资82.70
最新估值323.00
员工数40
成立年份2020
公司概况
- Companies
- Inocras
- Description
- Developer of a genome-based big data platform designed to pave the way for a new era of personalized precision medicine. The company's platform offers insights through the precise interpretation of full-length genome big data, enabling clients to employ the information effectively in their operations.
- Website
- —
- HQ Location
- San Diego, CA
- Year Founded
- 2020
- Keywords
- abi custom application, analytics platform, big data tooling, genome analysis, genome data, precision medicine, rare diseases therapy
- Competitors
- Geneious, Illumina, Sequentia Biotech
- Ownership Status
- Privately Held (backing)
- Company Financing Status
- Venture Capital-Backed
融资与估值
- Total Raised
- 82.70
- First Financing Date
- 01-Jan-2020
- First Financing Size
- 0.30
- First Financing Valuation
- —
- Last Financing Date
- 03-Aug-2026
- Last Financing Deal Type
- Later Stage VC
- Last Financing Size
- —
- Last Financing Valuation
- —
- Last Financing Status
- —
- Last Known Valuation
- 323.00
- Last Known Valuation Date
- 01-Nov-2023
- Last Known Valuation Deal Type
- Early Stage VC
- Valuation Estimate
- —
- Valuation Estimate Growth Rate
- 40.31%
- Active Investors
- Aimedbio, Asan Foundation, Big Move Ventures, DSC Investment, DT & Investment, Dunamu & Partners, Forest Partners (Korea), Ignite Innovation, IMM Investment, InterVest, Korea Investment & Securities, Loftyrock Investment, Ministry of SMEs and Startups, Moneyball Ventures, National Diversified Sales, Paratus Investment, Premier Partners, Regent Partners (Seoul), Samsung Venture Investment, Schmidt (South Korea), Seoul Clinical Laboratories, Shinhan Securities, Signite Partners, SOLiDX (South Korea), Timefolio Capital, V/Ventures, Woori Investment Bank
- # Active Investors
- —
- Acquirers
- —
团队与联系人
- Employees
- 40
- Employee Growth %
- —
- Employee History
- 2024: 40, 2023: 50, 2022: 29, 2021: 3
- Primary Contact
- Youngseok Ju
- Primary Contact Title
- Co-Founder & Board Member
- Primary Contact Email
- ysju@genomeinsight.net
- Primary Contact Phone
- +82 (0)42 863 0109
增长与经营
- Revenue
- 6.95
- Revenue Growth %
- 4.17%
- Growth Rate
- —
- Growth Rate % Change
- —
- Growth Rate Percentile
- —
- Size Multiple
- —
- Size Multiple % Change
- —
- Size Multiple Change
- —
- Size Multiple Percentile
- —
- Majestic Referring Domains
- —
- SimilarWeb Unique Visitors
- —
- SimilarWeb Unique Visitors Change
- —
- SimilarWeb Growth Rate
- —
- SimilarWeb Growth Rate Percentile
- —
- Success Probability Over Time – 1 Year
- 26%
- Success Probability Over Time – 3 Year
- 42%
- Success Probability Over Time – 5 Year
- 51%
记录来源：public.companies · 原始序号 #952 · 所有字段均按数据库原值展示。